Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$GEVA Baker Bros have a large position as well.
Top Institutional Holders
Holder Shares % Out Value* Reported
JANUS CAPITAL MANAGEMENT, LLC 1,246,390 4.05 79,008,662 Sep 30, 2013
Baker Brothers Advisors, LLC 10,273,182 33.42 651,217,006 Sep 30, 2013
Vanguard Group, Inc. (The) 867,605 2.82 54,997,480 Sep 30, 2013
BlackRock Fund Advisors 744,178 2.42 47,173,443 Sep 30, 2013
BB Biotech Ag 714,602 2.32 45,298,620 Sep 30, 2013
Capital Research Global Investors 3,515,772 11.44 222,864,787 Sep 30, 2013
Columbia Wanger Asset Management, L.P. 3,217,000 10.47 208,204,240 Dec 31, 2013
FMR, LLC 3,184,628 10.36 201,873,568 Sep 30, 2013
Capital World Investors 530,000 1.72 33,596,700 Sep 30, 2013
State Street Corporation 476,363 1.55 30,196,650 Sep 30, 2013
$NAVB $1.77 A lot of volume for being up only $.04, almost 4x daily average. Anyone have any ideas as to why?
Approved.
Yes , small amount.
$PGNX $5.33
Progenics Pharmaceuticals Presents Positive Data From a Phase 2 Trial of PSMA ADC in Patients With Chemotherapy Experienced Metastatic Castrate Resistant Prostate Cancer
PGNX), an oncology company focused on developing innovative approaches to targeting and treating prostate cancer, today presented a poster entitled A Phase 2 trial of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) at the American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium in San Francisco, CA. The Phase 2 trial assessed the anti-tumor activity and tolerability of its antibody drug conjugate, PSMA ADC, in patients with metastatic castrate resistant prostate cancer. A total of 83 patients who had progressive disease despite treatment with at least one taxane containing chemotherapy received PSMA ADC. Enrollment of a chemotherapy naive cohort is ongoing.
"We are encouraged by the tolerability and clear activity of PSMA ADC in this heavily pre-treated population," said Hagop Youssoufian, M.D., Executive Vice President, Research and Development. "For example, reductions in CTC's of more than 50% were seen in over 70% of patients treated."
Dr Youssoufian also said, "we look forward to the upcoming data in the less clinically advanced chemo naive setting, where our ADC technology may provide an even greater clinical benefit to men with prostate cancer."
"I've been encouraged by the response seen to date in our patients," said Daniel Petrylak, M.D., Professor of Medical Oncology at Yale Cancer Center, Clinical Research Program Leader for the Prostate and Urologic Cancers Program at Smilow Cancer Hospital at Yale-New Haven, and lead investigator on the trial. "I believe that the 2.3 mg/kg dose has been well tolerated," added Dr. Petrylak.
"We have long held the belief that PSMA expression would correlate with response, and were pleased to see that correlation in this trial. I was also pleased that another biomarker that measures low neuroendocrine disease also correlates and offers the ability to identify responders in this trial through the use of a simple blood test," said Mark R. Baker, CEO of Progenics.
An additional PSMA ADC related poster is being presented by EPIC Sciences entitled "Expression of Prostate-specific Membrane Antigen (PSMA) on Circulating Tumor Cells (CTC's) in Castration-resistant Prostate Cancer." The poster presentation is scheduled for Friday, January 31, at 11:30 AM PST.
A discussion with CEO Mark Baker and Senior Management of these findings will be webcast at 7:00 PM PST/10 PM EST on Thursday, January 30. The live webcast will be available in the Events section of the Progenics website, www.progenics.com. To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start. An archive of the event will be available for 90 days.
http://yhoo.it/1fqIahJ
$VNDA I didn't want to hold through PDUFA. Been holding this for a while.
$RGDX they must have done it in the first hour of trading because since 10:30 have seen no trades that size. Now looking at a 1 minute chart there have been no 10k lots traded today.
$RGDX don't know where you're seeing this.
MNKD MSN shows this data.
http://on-msn.com/1fu0jcw
$MNKD I don't know how often Yahoo updates their stats.
$MNKD Balance Sheet
Total Cash (mrq): 93.80M
Total Cash Per Share (mrq): 0.31
Total Debt (mrq): 405.68M
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 0.46
Book Value Per Share (mrq): -0.56
http://yhoo.it/1i8gH4F
$ALQA thanks oni.
$ALQA $9.10 uplisting to Nasdaq tomorrow.
http://bit.ly/1hFIBnS
$CHTP $4.59 form 4 filed 1/22/14
http://bit.ly/1hvR5xM
$CHTP $4.59 form 4 filed 1/22/14
http://bit.ly/1hvR5xM
True dat.
$MSTX I've had no problem getting fills today.
$LJPCD RG I got my shares on Friday afternoon @ Schwab.
$THLD $5.42 Jumped in this a.m. @ 5.29
$MSTX .79 I was tempted to buy while some people were buying @ .82 but bid/ask told me it was going lower so I waited til bid ask changed and that was @ .78. Thanks.
$MSTX in @ .78
$ONCS .461 pr from 1/14/14 Buying Opportunity in OncoSec Medical as Catalysts Approach
Earlier this morning, OncoSec Medical (ONCS.PK) announced its 2014 strategic update. The update provided a list of some of the upcoming events/catalysts that investors could expect. It appeared to have been a positive press release but shares dropped by as much as 15 percent before rebounding. The drop likely occurred because of investor impatience. Several investors may have been expecting a data release. Today’s sell-off reminds me of the age old adage that, “The stock market is a mechanism that transfers wealth from the impatient to the patient.” In order to be successful in the stock market, investors must know when to recognize value. After today’s sell-off, OncoSec Medical is extremely undervalued.
OncoSec Medical is a development-stage biotechnology focused on becoming the global leader in skin cancer treatment. In order to accomplish this, the company is focusing its efforts on immunotherapy, specifically, electroporation. Electroporation is the process of introducing DNA or chromosomes into bacteria or other cells using a pulse of electricity to briefly open the pores in the cell membranes. OncoSec Medical is evaluating this approach in several clinical trials which was the focus of today’s strategic update.
The strategic update contained several important pieces of information that investors should be aware of. One of the updates that stood out to me was the recent hiring of Dr. Robert Pierce, the new Chief Medical Officer “CMO” of OncoSec. Dr. Robert Pierce was the former Merck (NYSE:MRK) Research Labs Executive Director and member of the global anti-PD-1 development team. Over the past couple of months, anti-PD-1’s have been gaining a significant amount of attention in the medical community. The hiring of Dr. Robert Pierce adds significant credibility to OncoSec’s platform.
http://bit.ly/1arVYU8
$BIOD I just found it online.
http://1.usa.gov/1kCz7ir
$LJPCD I'm just going by what an account rep told me.
Yeah I just checked sec filings for $BIOD but not posted yet. Schwab must be slow on news.
$BIOD Do you have a link for that info?
$LJPCD I use Schwab and can buy shares of $LJPCD but to sell the shares I own I have to call Schwab.
$LJPCD The brokerages have to wait for the company(LJPCD) to give them a delivery date for post split shares.
$LJPCD The brokerages have to wait for the company(LJPCD) to give them a delivery date for post split shares.
The brokerages have to wait for the company(LJPCD) to give them a delivery date for post split shares.
cabos schwab allows it. Its called direct access trading.
$LJPC when does this rs happen?
$LJPC I'm long LJPC also. Just wasn't sure about that filing but my questions have been answered. Thanks
Thanks t2m. I thought it would put pressure on the pps with that many shares being sold.
$LJPC RG thanks I just saw the date 12/20/2013, didn't know it was older info.
$NWBO Alex concerning AF, if you throw enough sh@t at the wall sooner or later something sticks.